Nocardiosis medical therapy

Jump to navigation Jump to search

Nocardiosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Differentiating Nocardiosis from other Diseases

Epidemiology and Demographics

Causes

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Nocardiosis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Nocardiosis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Nocardiosis medical therapy

CDC on Nocardiosis medical therapy

Nocardiosis medical therapy in the news

Blogs on Nocardiosis medical therapy

Directions to Hospitals Treating Nocardiosis

Risk calculators and risk factors for Nocardiosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Medical Therapy

Nocardiosis requires at least 6 months of treatment, preferably with co-trimoxazole or high doses of sulfonamides. In patients who don’t respond to sulfonamide treatment, other drugs, such as ampicillin, erythromycin, or minocycline, may be added. Treatment also includes surgical drainage of abscesses and excision of necrotic tissue. The acute phase requires complete bed rest; as the patient improves, activity can increase. A new combination drug therapy (sulfonamide, ceftriaxone, and amikacin) has also shown promise.

Antimicrobial regimen

  • 1. Sulfonamide-based therapies [1]
  • 1.1 Pulmonary
  • Preferred regimen: TMP-SMX 10 mg/kg/day (TMP) in 2-4 divided doses IV for 3-6 weeks THEN 2 DS PO bid for at least 5 months
  • 1.2 Pulmonary alternatives
  • 1.3 CNS (AIDS, severe or disseminated disease)
  • Preferred regimen: TMP-SMX 15 mg/kg/day (TMP) IV for 3-6 weeks THEN 3 DS PO bid for 6-12 months
  • 1.4 CNS alternatives
  • 1.5 Severe disease, compromised host, multiple sites
  • 1.6 Sporotrichoid (cutaneous)
  • Preferred regimen: TMP-SMX 1 DS bid for 4-6 months
  • Note (1): Immunocompetent medicine use for 6 months; Immunosuppressed medicine for 12 months
  • Note (2): Treat based on host, site of disease and in vitro activity; Sulfonamide usually preferred, must treat for 6-12 months; Preferred drugs for resistant strains are Amikacin and/or Imipenem
  • Note (3): Seriously ill usually treated with IV Imipenem or Sulfonamide or Cefotaxime all potentially combined with Amikacin; less seriously ill treated with oral agents— especially TMP-SMX or Minocycline
  • 2. Sulfonamide alternatives
  • 2.1 Severe
  • 2.2 Mild

References

  1. Bartlett, John (2012). Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases. Burlington, MA: Jones and Bartlett Learning. ISBN 978-1449625580.

Template:WH Template:WS